Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab in Japanese adults with inadequately controlled chronic rhinosinusitis with nasal polyps
jRCT2031260006Completed
- Sponsor
- Sanofi
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of itepekimab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in endoscopic Nasal Polyp Score. Started Apr 2026; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on jRCT2031260006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260006.